Mictonorm Uno (Propiverine Hydrochloride)

Propiverine Hydrochloride, the active ingredient in Mictonorm Uno, is an antimuscarinic presented as an oral formulation for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients and is approved in the European Union for prescription use.

GNH USA supplies Mictonorm Uno as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets. The company ensures quality compliance with EU standards, adheres to stringent quality‑assurance protocols, and offers reliable distribution for healthcare providers worldwide.

Propiverine Hydrochloride is used to manage conditions within the overactive bladder disease family.

- Overactive bladder: reduces urinary urgency, frequency and improves bladder storage capacity. - Urinary urgency: alleviates sudden strong urge to void, helping patients regain control. - Urge incontinence: decreases episodes of involuntary leakage associated with bladder overactivity.

Propiverine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dry mouth - Constipation - Blurred vision - Dizziness

Serious or Rare Side Effects: - Acute urinary retention - Severe allergic reaction (anaphylaxis)

When prescribing Propiverine Hydrochloride, several precautions should be considered to ensure patient safety.

- Renal impairment: assess renal function and adjust therapy as needed. - Hepatic disease: monitor liver enzymes before and during treatment. - Glaucoma: use with caution in patients with narrow‑angle glaucoma. - Elderly patients: increased susceptibility to anticholinergic effects; monitor closely. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at room temperature below 25°C: keep in the original container, protect from moisture and light.

Propiverine Hydrochloride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase plasma levels of propiverine. - Anticholinergic drugs: additive anticholinergic burden can lead to severe dry mouth, constipation, and blurred vision.

Moderate Interactions (Monitor Closely): - Diuretics: may reduce therapeutic efficacy due to increased urine output. - Beta‑blockers: potential additive effects on bladder function. - Alcohol: may enhance dizziness and sedation.